NCT Number: NCT03007043
Genetic Variation in Gonadotropin and Gonadotropin Receptor Genes and Suboptimal Response
To evaluate the difference in the prevalence of the main FSHR polymorphism (ASN680Ser), as well as other, less studied, gonadotropin polymorphisms between ovarian response groups, following ovarian stimulation
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–38 year
Sex eligibility
Female
Study type
Observational
Primary location
Dexeus Salud de la Mujer, Barcelona, Spain
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age between 18-38 years old
- BMI 18-28
- Antral follicle count (AFC) > 9 or Anti-mullerian hormone (AMH) >1.1 ng/ml
- 1st or 2nd ovarian stimulation cycle for IVF/ICSI
- Planned to undergo ovarian stimulation with 150IU of rFSH in a fixed GnRH antagonist protocol
Exclusion criteria
- Antral follicle count (AFC) <9 and AMH<1.1 ng/ml
- PCOS patients according to the Rotterdam criteria
- Patients undergoing in vitro maturation (IVM)
- Untreated endocrine abnormalities
Treatment and study plan
Primary outcomes
-
prevalence of the main FSH receptor polymorphism
Time frame: 12 months
Sponsors and collaborators
Lead sponsor
Fundacion Dexeus
Other
Registry information
Official study title
Genetic Variation in Gonadotropin and Gonadotropin Receptor Genes as a Causative Factor of Suboptimal Response Following Ovarian Stimulation for IVF/ICSI. A Prospective Cohort Study
Important dates
- Study start
- 2016
- Primary completion
- 2019
- Study completion
- 2019
- First posted
- Dec 30, 2016
- Registry last updated
- Jan 27, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Performance Assessment of the MAGENTA Blast Algorithm for Embryo Prediction
NCT07464275
Fertility Disorders, Genital Diseases
Toronto, Ontario, Canada
View Trial DetailsFertility After Uterine Artery Embolization
NCT05271981
Connective Tissue Diseases, Fertility Disorders
Paris, France
View Trial DetailsSperm Selection by Microfluidic Separation Improves Embryo Quality
NCT03085433
Embryo Quality, Fertility Disorders
San Francisco, California, United States
View Trial DetailsASA 81 mg vs 162 mg During Frozen Embryo Transfer (FET)
NCT06128395
Fertility Disorders
Montreal, Quebec, Canada
View Trial Details